We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Hemodynamic Device Helps Maintain Stable Heart Function

By HospiMedica International staff writers
Posted on 07 Apr 2015
A miniature blood pump system helps support stable heart function and circulation during certain high-risk percutaneous coronary intervention (HRPCI) procedures.

The Impella 2.5 System is a heart pump intended for temporary use by patients with severe symptomatic coronary artery disease (CAD) and diminished (but stable) heart function who are undergoing a HRPCI procedure (such as balloon angioplasty and stenting), but are not candidates for surgical coronary bypass treatment. More...
An interventional cardiologist first guides the Impella 2.5 into position via percutaneous angioplasty, guiding the loaded tip of the catheter through the arteries and into the left ventricle.

Throughout the procedure, the system draws blood from the left ventricle and pumps it into the aorta at rates of up to 2.5 L/min. An external controller and monitor turns the pump on and off, measures heart function, and allows healthcare providers to adjust it as necessary to maintain stable heart function and circulation during the procedure. The temporary circulatory support provided by the system allows a longer and more thorough procedure by preventing episodes of hemodynamic instability—such as poor circulation and low blood pressure—due to temporary abnormalities in heart function.

Studies have shown that complex, high-risk patients undergoing protected percutaneous coronary intervention (PCI) with Impella 2.5 support experience reduced adverse events, improved quality of life, and can return home faster. Fewer later adverse events may occur in patients undergoing HRCPI with the pump, compared to those undergoing HRPCI with an intra-aortic balloon pump (IABP). The Impella 2.5 System is a product of Abiomed (Danvers, MA, USA), and has been approved by the US Food and Drug Administration (FDA).

“As heart disease patients get sicker, more complex, and desire minimally invasive solutions, there are few options available to them to help improve their quality of life in a cost effective manner," said Michael Minogue, chairman, president, and CEO of Abiomed. “We are excited that Impella has been recognized as a device that can potentially become the new standard of care with a “first of its kind' approval.”

All patients undergoing HRPCI are at some risk for complications related to decreased heart function and lowered blood pressure during the procedure, but patients in need of treatment for extensive or critically located CAD who are already experiencing diminished heart function also face at high risk for serious complications.

Related Links:

Abiomed
Impella 2.5 CP animation



Gold Member
12-Channel ECG
CM1200B
Radiology Monitor
MDNC-6121 Barco Nio Color 5.8MP
Desk Aneroid Sphyg
Diagnostix 750D+
Multi-Chamber Washer-Disinfector
WD 390
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Artificial Intelligence

view channel
Image: Clinical LLM Performance Improves by >300% When Provided with High-Quality Real-World Evidence in New Precision Medicine Benchmark (Photo courtesy of Atropos Health)

New Benchmark Highlights Evidence Gaps in AI Responses to Clinical Questions

Many clinical decisions still rely on limited evidence, while most artificial intelligence benchmarks overlook the patient context that shapes real-world care. General large language models can also struggle... Read more

Critical Care

view channel
Image: Lead study author Ramy Ghanim (left) and co-author Joy Jackson test an small implantable device alongside Assistant Professor Alex Abramson. In a new Science paper, they describe a networking system that connects therapeutic implants and wearable devices by using the body’s natural conductivity to send tiny signals. (Photo courtest of Georgia Tech)

Bioelectronic Network Enables Devices to Communicate Through Body Tissue and Coordinate Therapy

Wearable sensors and implanted therapeutic devices can be difficult to coordinate when signals must pass through the body. Conventional wireless signals do not travel well through tissue, while the antennas... Read more

Point of Care

view channel
Image Credit: 123RF

Continuous Glucose Monitoring Identifies Cardiometabolic Risk in Adults Without Diabetes

Dysglycemia—abnormal blood glucose regulation—can fluctuate throughout the day and often escape conventional screening. Clinicians typically rely on fasting plasma glucose and hemoglobin A1c, which offer... Read more

Business

view channel
Image: LigaSure RAS Maryland, designed for the Valleylab FT10 platform on Hugo RAS, seals and cuts vessels, tissue, and lymphatics up to 7 mm in diameter (Photo courtesy of Medtronic)

Medtronic Receives FDA Clearance for Vessel-Sealing Instrument for Robotic Surgery

As robotic-assisted surgery expands across U.S. hospitals, teams increasingly seek energy instruments with the familiarity and performance of tools used in open and laparoscopic procedures.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.